Build a new drug empowerment ecosystem, Medicilon Academician Innovative Drug Maturation Center - New Drug Ecological Assistance Platform Press Conference was successfully completed

 On November 30, the "Focus on the development of innovative drugs and promote the upgrading of the industrial chain - Medicilon Academician Innovative Drug Maturation Center - New Drug Ecological Assistance Platform Press Conference" hosted by Shanghai Medicilon Inc. (Medicilon) was grandly held.  More than 100 expert representatives from the government, industry, academia, and financial industry jointly witnessed a brand-new new drug empowering ecosystem, the technology empowerment platform of the Medicilon Academician Innovative Drug Maturation Center, the front-end new drug investment and financing support platform and the back-end new drug R&D trading platform ecological chains.

Academician Project Settlement Signing
Medicilon helps more scientific research results blooming 

 

Academician Project Settlement Signing

At the signing ceremony, Professor Shuangqing Peng, Chief Scientific Officer of Medicilon, and Dr. Jian Liu, President of the Drug Discovery Division, signed the contract with Guoqiang Lin and Academician Li Jia on behalf of Medicilon.

Taking this signing as an opportunity, the two parties will have in-depth linkage and sincere collaboration, accelerate the implementation of collaboration projects, and achieve complementary advantages, mutual benefit, win-win, and common development.

Medicilon Academician Innovative Drug Maturation Center - New Drug Ecological Assistance Platform 
Born to build a new drug R&D ecosystem

Medicilon Academician Innovative Drug Maturation Center - New Drug Ecological Assistance Platform Officially Released

Under the attention of the whole audience, Academician Li Jia, Deputy Director of Zhangjiang Administration Bureau Jun Wu, and Medicilon Chairman Jinzhang Chen took the stage to water the ecological tree together.  This means that all parties will work together to promote the ecological construction of the biomedical industry and work together to water it into a towering tree with lush branches and leaves.

Medicilon Empowering Ecosystem - New Drug Investment and Financing Assistance Platform
Aims to provide financial support for new drug research and development

Medicilon's empowering ecology and new drug investment and financing support platform aims to provide financial support for new drug research and development.  Medicilon has cooperated with a number of financial institutions to create a new investment and financing support platform to provide stable financial support for all aspects of new drug research and development, testing, and launch.

Investment and Financing Assistance Consultant Recruitment Ceremony

Next, Dr. Jinzhang Chen and Dr. Chunlin Chen took the stage and awarded employment certificates to Ling Cen, Founding Director of Fudan University School of Management, Zhenhua Zheng, Managing Partner of Shenzhen Triwise International Capital Management, Ronggang Xie, Partner of Loyal Valley Capital, and other investment and financing consultants.  We look forward to them providing valuable suggestions and support for the development of Medicilon’s empowering ecosystem and new drug investment and financing platform in the future.

Medicilon Empowers Ecosystem - New Drug R&D Trading Platform
Facilitate the transformation and trading of phased results of new drug research and development

The new drug investment and financing assistance and empowerment platform aims to provide financial support for new drug research and development, while the new drug research and development trading platform facilitates the transformation and trading of new drug research and development stage results by establishing an open and transparent platform.  At the same time, it also encourages more scientific researchers to invest in the research and development of new drugs, helping scientific research results to be better displayed and rewarded.

Dr. Xianlian Wang, Head of Scientific Research of Medicilon Pharmalego® Platform

In order to meet the market demand for high-end intermediates, Medicilon has established an e-commerce platform for pharmaceutical intermediates - Pharmalego (cn.pharmalego.com).  Dr. Xianlian Wang, Head of Scientific Research of Medicilon's Pharmalego® platform, introduced that Pharmalego integrates the production, sales and customized synthesis services of high-end pharmaceutical intermediates.  Its core products include PROTAC® Building Blocks, nucleotides, ADC linkers, delivery systems, etc. , which can provide products from technical level, research level, reference standard level.

Whatever you do with accumulated strength, you will be victorious in everything you do; whatever you do with wisdom, you will be successful in everything.  The Medicilon Academician Innovative Drug Maturation Center - New Drug Ecological Assistance Platform has since embarked on a new journey, which is also an expedition full of missions and dreams.  Facing the future, Medicilon will firmly grasp the requirements of the times for unity and struggle, adhere to integrity and innovation.  Relying on Medicilon's empowering ecology and new drug investment and financing support platform, one-stop biomedical preclinical R&D service platform, and new drug R&D and trading platform ecosystem, multiple measures are taken to help the transformation of scientific and technological achievements and help achieve the goal of "Healthy China 2030"!